Cabozantinib active in castration-resistant prostate cancer
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. 19 in the Journal ...
Dec 3, 2012
0
0